Low-grade and chronic systemic inflammation is associated with the development of cardiometabolic diseases, including myocardial infarction, stroke, diabetes, heart failure and more. Low-grade systemic inflammation precedes the onset of cardiovascular events by many years, and inflammation is a consistent predictor of cardiovascular risk. Clinical studies have shown that reducing inflammation can potentially lead to cardiometabolic benefits, and reducing inflammation remains an active area of research that also has important clinical implications, including in the prevention and management of obesity, dyslipidemia, heart failure, chronic kidney disease, hypertension, and type 2 diabetes.

At 2023 CMHC Spring, world-renowned experts will present on the latest advances in the prevention and treatment of cardiometabolic disease, with a special focus on inflammation.  The conference will focus on the practical approaches on how to identify and address inflammation, as well as how to optimize guideline-directed care for cardiometabolic patients.

The meeting will include extensive expert panel discussions, as well as ample opportunities for audience Q & A, with the goal of enhancing the interactions with thought leaders and to help clinicians walk away with practical advice to apply directly to patient care.